The size of the European Veterinary Vaccines Market is poised to reach USD 3.13 Billion by 2027 from USD 2.46 Billion in 2022, growing at a CAGR of 4.97% from 2022 to 2027.
Vaccination protects animals from specific infectious diseases and may be carried out routinely or potentially in an emergency. Immunization of animals used for food can also help protect consumers against zoonotic pathogens such as salmonella.
The European Veterinary vaccines market is as old as the concept itself, and the newest products are significantly available throughout the market. The farmers and animal husbandry owners seem well versed in the idea of animal vaccination. But the real test lies in the stringent guidelines for animal vaccines testing as per EU regulations. It prevents or at least hardens the route for new players to enter the market. The market has also undergone considerable progress during the past few years with the growing usage of continuous cell lines as a substrate and the embracing of fermentor technology for antigen production. These vaccines are produced for administration by parenteral or oral routes depending on the vaccine characteristics.
Growing prevalence of animal diseases, rising incidences of zoonotic diseases in humans, increasing investments by leading players, various government agencies, and animal associations; continuous innovations; raising awareness against antimicrobials is driving the vaccine producers to invest significantly in the development of new products.
However, rising maintenance costs for the storage of vaccines and increasing adoption of a vegetarian diet in major economies due to the increased risk of obesity and other chronic diseases are key restraints.
This research report on the Europe Veterinary Vaccines Market has been segmented and sub-segmented into the following categories:
Based on technology, the canine vaccines segment accounted for a slightly larger share (in terms of revenue) than the feline vaccines segment due to the higher average cost allied with canine vaccination.
Regionally, the European region is leading the Global Veterinary vaccines Market in terms of consumption. The French veterinary vaccines market is expected to flourish between 2020 to 2025 as players in France are manufacturing veterinary vaccines according to the European pharmacopeia & OIE norms' requirements with specific needs. Vaccine manufacturers are using purified recombinant proteins for vaccination to identify the target. Increasing awareness of zoonotic diseases is a significant contributor to the France veterinary vaccine market. In addition, rising healthcare facilities and infrastructure show a positive impact on the veterinary vaccine and related products in France. The key players of France veterinary vaccine market are Boehringer Ingelheim, Zoetis Inc., and Bayer Healthcare.
The Italian veterinary vaccines market holds dominant shares of the following France due to the rising number of infectious diseases. Rising awareness about animal health and vaccines will drive the veterinary vaccines market. The Italian veterinary healthcare market developed animal therapeutic products to grow the market. The export & business investment market dominates Italy. It will open lucrative business opportunities to the key companies to increase their Italian veterinary vaccines market demand.
Prominent companies playing an active role in the European Veterinary vaccines Market are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health. Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health. Inc., Merck & Co. Inc., and Protein Sciences.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com